The revenue exists.
It requires no new patients. No new services that pharmacists are not already qualified to deliver. No capital investment beyond a platform subscription.
Most independent pharmacies are not collecting it.
Not because they are unaware that it exists. Because they have not built the system that makes collection consistent.
What MTM actually is
Medication therapy management is a clinical service in which a pharmacist reviews a patient's complete medication regimen to identify and resolve drug therapy problems.
Not a new clinical concept. A billable service that has existed within Medicare Part D since the program's inception.
The Comprehensive Medication Review — the CMR — is the primary service. A complete, interactive review of everything the patient takes. Prescriptions, over-the-counter medications, supplements. Every drug therapy problem identified. Every gap in therapy addressed. A Medication Action Plan and a Personal Medication List delivered to the patient.
The Targeted Medication Review — the TMR — is a shorter follow-up. Focused on specific concerns that have emerged since the last review. Still billable. Still valuable.
Both services are covered by Medicare Part D at no out-of-pocket cost to the patient.
Both are consistently underused by independent pharmacies.
Two systems. One meaningful difference.
Consider two pharmacies.
Pharmacy A decides to offer MTM. They register on the billing platform. They complete encounters when patients ask about it or when a plan notification prompts an interaction. Three to five encounters per month. Revenue is inconsistent. The program feels unreliable. They eventually stop.
Pharmacy B decides to offer MTM. They build a weekly eligibility review process. A senior technician runs the patient list against eligibility criteria every Tuesday. An outreach list is generated. Calls go out by Thursday. Encounters are scheduled. Revenue is predictable.
Pharmacy A is not doing less clinical work than Pharmacy B. Pharmacy B is not doing more.
The difference is entirely operational.
Pharmacy B generates between $2,000 and $4,000 per month. Pharmacy A generates intermittent small amounts and eventually concludes that MTM does not work for their pharmacy.
Pharmacy A has diagnosed the wrong problem.
Who qualifies
The eligibility criteria for MTM under Medicare Part D require patients to have multiple chronic conditions, to take multiple Part D drugs, and to be likely to incur drug costs above a CMS-defined annual threshold.
In practice, this describes a large proportion of the Medicare patients most community pharmacies serve daily.
The consistent profile: over sixty-five, two or more chronic conditions from a list that includes diabetes, hypertension, heart failure, hyperlipidemia, respiratory disease, bone disease, and mental health conditions, taking eight or more Part D-covered medications.
Most independent pharmacies with meaningful Medicare volume have more eligible patients than they realize.
The problem is not scarcity of eligible patients. It is the absence of a recurring system for finding and reaching them.
How to identify your eligible population
Step 1
Pull a report of all active Medicare Part D patients who have filled at least one prescription in the past ninety days. Most pharmacy management systems can generate this. If yours cannot, contact your PMS vendor before assuming it is impossible.
Step 2
Filter for patients taking eight or more unique active medications. This is your core eligible pool. It is typically 15 to 30 percent of active Part D patients. It is almost always larger than owners expect.
Step 3
Register on the MTM vendor platforms your patients' plans use. Outcomes MTM and Mirixa are the two primary platforms in the US context. Each connects you to the Part D plans in their network, provides documentation infrastructure, and handles claims submission. Registration is required before you can access plan enrollment lists or submit claims.
Step 4
Cross-reference your internally identified pool against plan enrollment lists. Plans share their MTM enrollment data for patients at your pharmacy through these platforms. This step confirms which of your identified patients are formally eligible under their specific plan's program.
Step 5
Prioritize outreach by complexity and relationship depth. Patients with the most complex regimens and the strongest existing pharmacy relationships accept at the highest rates. Start there.
The outreach call that actually works
The framing of the outreach call determines the acceptance rate.
This framing does not work:
"Hi, I am calling from the pharmacy to let you know that your insurance covers a medication review service at no cost to you."
That sounds like a sales call. Most patients disconnect.
This framing works:
"Hi, this is your pharmacist calling. I have been reviewing your medication list and I would like to schedule some time with you to go through everything you are taking together. Your Part D plan covers this completely and I think it would be genuinely useful given what you are managing. It takes about thirty minutes."
Personal. Specific. Clinical in framing. Centered on that patient's particular situation.
The relationship you have already built is the primary asset in MTM outreach. Use it.
How billing works
MTM billing under Medicare Part D uses HCPCS codes.
The CMR is billed using code 0996F for a completed comprehensive medication review. The TMR uses code 0597F for a completed targeted review.
A completed CMR typically reimburses between $75 and $175 depending on the plan. A completed TMR typically reimburses between $15 and $40. Verify current rates with your specific plans, as figures change.
Documentation that supports clean billing
The requirements for a completed CMR are specific.
Encounter date and duration. Complete medication list as reviewed. Drug therapy problems identified. Interventions recommended or made. Medication Action Plan delivered to the patient. Personal Medication List delivered to the patient.
The most common billing failure is incomplete documentation — not because pharmacists skip clinical steps, but because documentation is reconstructed after the encounter rather than completed during it.
Real-time documentation during the encounter takes the same time as post-encounter reconstruction. It produces significantly more complete records. It eliminates the risk that documentation does not get done because the next patient arrived first.
The MTM platforms provide structured documentation templates that prompt for every required element in real time. Use the platform. Do not try to build your own system.
The billing submission error that slows cash flow
Monthly submission of accumulated claims.
It feels efficient. It is not.
Weekly submission generates faster reimbursement. More importantly, it surfaces rejected claims quickly enough to correct and resubmit before the correction window closes.
A rejected claim discovered three weeks after submission is often outside the window. The same claim discovered the following week is correctable.
Submit weekly. This is not optional if cash flow is a priority.
What consistent MTM revenue looks like in practice
A single-store independent pharmacy in a mid-sized southern US city implemented the operational system described in this article.
Month one: eleven CMRs, seven TMRs, approximately $1,100 in additional revenue.
Month six: eighteen to twenty-two CMRs, twelve to fifteen TMRs, approximately $2,400 per month consistently.
Pharmacist personal time: eight to ten hours per month for encounters. Technician time: two to three hours per week for identification, outreach, and documentation coordination.
"The ratio of revenue to time invested is probably the best in anything we do," the pharmacist said. "It is not passive income. But it is close."
A pharmacy in a rural market with a smaller patient panel generated between $1,600 and $1,800 per month.
"For us it is not life-changing but it is real. It is money that was always there and we just were not collecting it."
Both pharmacies did nothing different clinically than they had done before.
They built a system.
What MTM looks like outside the United States
The US Medicare Part D MTM framework is country-specific. Equivalent programs exist elsewhere under different names.
United Kingdom. The NHS Advanced Pharmacy Services program includes the Medicines Use Review and the New Medicine Service — community pharmacist consultations billable separately from dispensing. The New Medicine Service has strong evidence for improving adherence and is actively promoted within NHS England's community pharmacy strategy.
Australia. The MedsCheck and Diabetes MedsCheck programs provide government payment for pharmacist medication reviews for eligible patients. Chronically underused by independent pharmacies in the same way US MTM is underused.
Canada. Some provincial drug benefit programs and employer-sponsored plans include pharmacist medication review services with separate billing structures. The variation between provinces is significant and requires checking your specific provincial framework.
In every case, the principle is identical.
Pharmacists can generate additional revenue by providing structured medication review services. The funding mechanisms exist. They are consistently underused.
The reason most pharmacies leave this uncollected
It is not clinical uncertainty. It is not patient unwillingness. It is not billing complexity.
It is the absence of a scheduled, recurring process that someone is specifically responsible for running.
MTM revenue does not arrive because you are available to provide the service.
It arrives because someone in your pharmacy is identifying eligible patients on a schedule, reaching them with a specific call script, documenting encounters in real time, and submitting claims weekly.
That system does not build itself.
It takes roughly one afternoon to set up and one afternoon of coordination per week to operate.
The return for most pharmacies with meaningful Medicare volume is between $1,500 and $4,000 per month.
That calculation has been available to every independent pharmacy for years.
Whether the system gets built this week is a management decision, not a clinical one.
Read next on Blinkerhub:
MTM completion rate is also one of the metrics that directly affects your Part D reimbursement tier. If you have not yet audited what you are actually being paid at the plan level, the reimbursement breakdown is the right next read.
If you want to build a second non-PBM revenue stream alongside MTM, the physician relationship compounding strategy is the most accessible place to start.
And if the question of whether the independent pharmacy business is worth building at all is the one sitting underneath everything else, we have answered it directly.
Blinkerhub is a free weekly intelligence newsletter for independent pharmacy owners worldwide. Not affiliated with any PBM, chain pharmacy, trade association, or pharmacy software vendor. Published every Tuesday at pharmacy.blinkerhub.com.
MTM billing codes, reimbursement rates, and eligibility criteria change periodically. Verify current figures with your Part D plan contacts and MTM vendor platforms before implementing your program.